Nearly one in four older women report incontinence
October 1st 2004San Francisco--Urinary incontinence remains a common medical condition in older women, even in those who rate their health as "good" or "excellent." Nearly 12% of elderly women experience stress, urge, or other form of incontinence, according to findings from an analysis of the Health, Aging, and Body Composition study published in Obstetrics & Gynecology (2004; 104:301-7). The condition is more prevalent in Caucasian women than in African-Americans, the study found.
Early or late recurrence? Little difference after all
October 1st 2004Houston--Early or late recurrence after induction BCG therapy with or without maintenance BCG for high-risk bladder cancer confers a significant increased risk of death, a finding that contradicts the widely held belief that late recurrence has less adverse impact on survival, according to data from a large clinical database.
Urologists should spearhead testosterone trials
October 1st 2004New York--It is up to urologists to take the lead in conducting clinical trials to define the safety and benefits of testosterone therapy in older men, according to E. Darracott Vaughan, Jr, MD. Dr. Vaughan, one of two urologists who served on an Institute of Medicine committee assessing the need for clinical trials of testosterone replacement, provided an update on the committee's report and its significance to urologists during the AUA annual meeting.
Short-term androgen therapy plus RT boosts survival
October 1st 2004A 6-month course of androgen suppression therapy following radiation treatment for clinically localized prostate cancer confers survival benefits similar to those seen with longer courses of androgen blockade (>3 years), according to a recent study from Brigham and Women's Hospital and the Dana Farber Cancer Institute, Boston. The study also suggests that only partial blockade with a luteinizing hormone-releasing hormone (LHRH) agonist may be sufficient.
Shared pockets spell tax trouble for ‘related’ parties
October 1st 2004Excessive compensation, in the IRS's eyes at least, indicates that the principal/shareholder was attempting to avoid the double-tax due on dividend income-once at the corporate level and again as the personal income of the recipient.
A modern approach to nocturia management
October 1st 2004Nocturia is a bothersome condition brought on by a host of factors in a broad segment of the population, particularly the elderly. It may have a significant impact on quality of life, and the associated sleep deprivation may lead to psychological and physical illness. Management of nocturia can only be pursued once the specific etiology of the condition is defined. This article describes a modern approach to pinpointing the underlying etiology, which in turn leads to appropriate treatment.
OK to bill orchiopexy with hernia repair, CPT says
October 1st 2004Q A pediatric urologist I code for is concerned that we cannot bill/code for both orchiopexy and a hernia repair done during the same operating room session. Do you have any documentation on this matter? When you look up 54640 in CPT 2004, it references, "For inguinal hernia repair performed in conjunction with inguinal orchiopexy, see 49495-49525." In the Medicare Correct Coding Guidelines, I do not see any edits stating not to bill both procedures together.
Primary hormonal therapy up, RP down, CaPSURE shows
October 1st 2004Since its inception in 1995, the Cancer of the Prostate Urologic Research Endeavor has become one of the world's largest databases on prostate cancer. CaPSURE shows a rapidly evolving picture of how the disease is treated and the typical patient confronting it. In this exclusive Urology Times interview, Peter R. Carroll, MD, CaPSURE's principal investigator, discusses these trends and the forces driving them. The interview was conducted by UT Editorial Consultant Richard D. Williams, MD, professor and chairman of the department of urology, University of Iowa, Iowa City.
Single chemotherapeutic agent may preserve testis
October 1st 2004New Orleans--Four-year results of a phase III clinical trial suggest that a single dose of the chemotherapeutic agent carboplatin (Paraplatin) is as safe and effective as adjuvant 3-week-long radiation therapy following orchiectomy of seminomatous testis cancer. More surprising was the observation that there were fewer germ cell cancers in the other testis, British oncologists reported at the American Society of Clinical Oncology annual meeting.
Rare non-motile sperm points to vasectomy success
October 1st 2004Toronto--Patients who show evidence of rare non-motile sperm after undergoing vasectomy will eventually become azoospermic-marking vasectomy success. However, patient compliance post-vasectomy remains low, despite aggressive pre- and postoperative counseling, University of Toronto researchers report.
Hematuria guidelines boost bladder Ca survival rate
October 1st 2004Honolulu--A standardized hematuria evaluation that follows recommendations of the AUA Best Practice Guidelines appears to improve survival in patients with transitional cell carcinoma of the bladder, results of a retrospective analysis of a longitudinal database suggest.
New hope for infertility: Detecting and treating sperm DNA fragmentation
September 21st 2004An estimated 2.6 million couples in the United States experience problems with fertility, and numerous factors may be involved in both the male and the female partners. In up to 40% of infertile couples, male factor infertility plays a contributing role. For many years, the evaluation of male infertility has relied on-and been limited to-semen analysis, which measures sperm count and assesses sperm motility and morphology. More recently, new technologies have evolved that measure DNA fragmentation in sperm. Clinical studies have shown that sperm with elevated levels of DNA fragmentation are a strong predictor of reduced male fertility. Many factors-infection, diet, illicit drugs, some prescribed and over-the-counter medications, lack of sleep, stress, high fever, elevated testicular temperature, air pollution, alcohol, cigarette smoking, toxin exposures, advanced age-may result in DNA fragmentation.Now on the market is a dietary supplement called Proxeed?, which has been designed to enhance and support the quality of sperm. This supplement provides ingredients that contribute to the metabolic processes in the cells that manufacture sperm. Clinical data have shown that the ingredients in Proxeed? may potentially optimize sperm motility, speed, count, morphology, and concentration.Recently, Mark Perloe, MD, an endocrinologist and fertility specialist, posed questions to Phillip Werthman, MD, a board certified urologist and fellowship-trained andrologist, on the use of DNA testing of sperm, on the implications of DNA fragmentation, and on the benefits of dietary fertility supplements in optimizing the reproductive health of men. The following is a report of Dr. Werthman’s answers to these questions.
Articles do not properly inform public on prostate cancer screening
September 16th 2004Articles on prostate cancer and colon cancer screening in high-circulation consumer magazines do not offer the necessary information for readers to make an informed decision, according to a recent study in the Journal of General Internal Medicine (2004; 19:843-8).
'PSA era is over in the United States,' leading researcher says
September 16th 2004PSA has lost its value as a screening tool for prostate cancer and does nothing more than indicate the size of the prostate gland, according to a study led by Thomas A. Stamey, MD, and published in the October issue of the Journal of Urology (2004; 172:1297-1301).